多西紫杉醇联合顺铂治疗晚期胃癌的临床研究-东南大学学报医学版

多西紫杉醇联合顺铂治疗晚期胃癌的临床研究

单位：1.东南大学医学院附属江阴医院,肿瘤科,江苏,江阴,214431； 2.东南大学附属中大医院,肿瘤科,江苏,南京,210009

分类号：R730.54

出版年·卷·期（页码）：2007·26·第一期（25-26）

摘要：

目的:观察多西紫杉醇联合顺铂治疗晚期胃癌的临床效果及毒性.方法:27例晚期胃癌患者应用多西紫杉醇75mg·m-2第1天静脉滴注,顺铂 25mg·m-2第1～3天静脉滴注,21d为1个周期,2个周期后评价疗效.结果: 27例中完全缓解1例,部分缓解9例,总有效率为37.0%.临床受益反应评价有效者共20例,占74.1%.主要毒副作用为骨髓抑制和脱发,但患者能较好耐受.结论:多西紫杉醇联合顺铂方案是目前治疗晚期胃癌较理想的二线方案.

参考文献：

[1] AJANI J A. Docetaxel for gastric and esophageal carcinomas, 2002(6)
[2] BURRIS H A, MOORE M J, ANDERSON J. Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer:a randomized trial, 1997
[3] SULKED A, SMYTH J, SESSA C. Docetaxel(Taxotere) in advanced gastic cancer:results of aphaseⅡclinical trial.EORTC Early Clinical Tricals Group, 1994
[4] TAGUCHI T, SAKATA Y, KANAMARU R. Latephase Ⅱ clinical study of RP 56976 (docetaxel) in patients with advanced recurrent gastric cancer:a Japanese Cooperative Study Group trial(group A), 1998
[5] MITACHI Y, SAKATA Y, OHTSU A. Docetaxel and cisplatin in patients with a advanced or recurrent gastric cancer:a multi-center phaseⅠ/Ⅱ study. 2002(5). doi:10.1007/s101200200028
[6] KUNISAKI C, IMADA T, YAMADA R. Phase II study of docetaxel plus cisplatin as a second-line combined therapy in patients with advanced gastric carcinoma, 2005(4)

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录